What is Lassogen?
Lassogen, Inc. is a pioneering biotechnology firm dedicated to the development of a new class of programmable medicines known as Lassotides. By leveraging the unique structural properties of lasso peptides, the company aims to bridge the gap between the high specificity of antibodies and the pharmacological advantages of small molecules. This innovative approach is designed to address complex disease indications that have historically proven resistant to conventional therapeutic modalities. With a leadership team possessing over a century of combined industry expertise, Lassogen is strategically positioned to disrupt the current pharmaceutical landscape by offering more effective, targeted treatment options for patients with significant unmet medical needs.
How much funding has Lassogen raised?
Lassogen has raised a total of $4.5M across 1 funding round:
Angel/Seed
$4.5M
Angel/Seed (2020): $4.5M with participation from Better Ventures, Playground Global LLC, Foothill Ventures, and First In Ventures
Key Investors in Lassogen
Better Ventures
Better Ventures is a mission-driven venture capital firm that invests in early-stage startups focusing on leveraging science and technology to create a sustainable economy that benefits people and the planet.
Foothill Ventures
Foothill Ventures is a multi-stage venture capital firm that partners with technical founders to build transformative companies in the deep tech, life sciences, and software sectors.
Playground Global LLC
Playground Global is a venture capital firm that provides capital and operational support to early-stage companies working on deep technology and scientific breakthroughs.
What's next for Lassogen?
With this major strategic investment, Lassogen is poised to transition from its foundational research phase into more advanced preclinical development. The company will likely focus on scaling its proprietary platform to optimize the delivery and efficacy of its Lassotide candidates. Future milestones will center on expanding the therapeutic reach of its pipeline, potentially entering partnerships with larger pharmaceutical entities to facilitate clinical trials. As the company matures, the focus will shift toward establishing a robust intellectual property portfolio and demonstrating the scalability of its manufacturing processes, ensuring that its programmable medicines can be effectively deployed to address a broader spectrum of challenging human diseases.
See full Lassogen company page
